Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis. InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in […]
BioDelivery Sciences, Teva settle patent fight over opioid dependence treatment
BioDelivery Sciences (NSDQ:BDSI) said today that it inked a deal with Teva Pharmaceuticals (NYSE:TEVA) to settle claims that the generic form of BioDelivery Sciences’ Bunavail buccal film that Teva is trying to bring to market in the U.S. infringes upon several patents owned by the Raleigh, N.C.-based company. As part of the deal, which was reached in […]
Teva reintroduces generic Depo-Provera contraceptive in U.S.
Teva Pharmaceuticals (NYSE:TEVA) said today that it is reintroducing the generic equivalent to the Depo-Provera contraceptive in the U.S. The injectable medroxyprogesterone acetate suspension brought in $211 million in sales this year in the U.S., according to the Jerusalem-based pharma giant. “This reintroduction brings an additional product to a market that was previously lacking in options,” Hafrun […]
Teva sells off the rest of its women’s health assets in $2.5B deal
After the company divested its Paragard intrauterine device assets for $1.1 billion in cash last week, Teva Pharmaceuticals (NYSE:TEVA) announced today that it plans to sell off the rest of its global women’s health biz. Combined with proceeds from its Paragard deal, the sale of Teva’s global women’s health assets will total $2.48 billion, the company […]
Investors sue Teva over $41B Actavis deal
Teva Pharmaceuticals (NYSE:TEVA) and a handful of current and former executives were hit with a lawsuit yesterday alleging that the drugmaker hid the negative fallout linked to its $40.5 billion purchase of Actavis Generics. Barry Baker, a Teva investor, claimed that the company, former CEO Erez Vigodman, ex-CFO Eyal Desheh and interim CEO Yitzhak Peterburg issued […]
House Dems launch MS drug pricing probe
Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of an investigation into why prices for multiple sclerosis drugs have nearly quadrupled since 2004. Reps. Elijah Cummings (D-Md.) and Peter Welch (D.-Mass) penned inquiries to Bayer (ETR:BAYN), Biogen (NSDQ:BIIB), EMD Serono, Novartis (NYSE:NVS), Roche (OTC:RHHBY), Sanofi Aventis (NYSE:SNY) and Teva Pharmaceuticals (NYSE:TEVA). […]
Teva wins FDA nod for Qvar RediHaler device
Teva Pharmaceuticals (NYSE:TEVA) said today that the FDA approved its Qvar RediHaler breath-actuated inhaler for the maintenance treatment of asthma in patients ages 4 and older. The device, which is not indicated for acute bronchospasm, is slated to become commercially available during the first quarter of 2018. Unlike conventional metered-dose inhalers, the Qvar RediHaler does not […]
Teva lowers outlook after Q2 EPS misses estimates
(Reuters) – Israeli drugs group Teva Pharmaceuticals (NYSE:TEVA) reported a steeper than expected drop in second-quarter earnings on Thursday, due to weaker prices in the United States, and cut its interim dividend by 75 percent. Along with a substantial reduction in its 2017 outlook, shares in the world’s largest generics drugmaker tumbled 16.5 percent in Tel Aviv […]
Employee alleges Teva hid antitrust, bribery probes
Teva Pharmaceuticals (NYSE:TEVA) employee Robert Huellemeier launched a proposed class action suit against the generic drugmaker this week, alleging that the company hid that it was under investigation for price fixing and bribery. Huellemeier, who bought TEVA shares through a company program, accused the company of leaving out any mention of multiple investigations in regulatory notes […]
EU antitrust officials charge Teva in ‘pay-for-delay’ deal
Antitrust regulators in the European Union charged Teva Pharmaceuticals (NYSE:TEVA) today, accusing the company of arranging an illegal deal with Cephalon to delay the sale of a cheap generic version to Cephalon’s sleep disorder drug, modafinil. The EU competition officials have unleashed a series of fines against an array of companies in recent years over similar […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn